Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

96.91 -1.25 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
58 59 Next >
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
This New Drug Could Be Gilead Sciences' Growth Catalyst
Another potential blockbuster drug in Gilead's hands. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
Which of these companies is better able to replace declining COVID-19-related sales? 
Via The Motley Fool
FTX Exchange's Assets Worth $3.5B Held By Bahamian Regulators, Italy PM To Meet Intel Over Chip Investment, New Oral COVID Antiviral Might Be Better Than Pfizer's Paxlovid: Today's Top Stories
Reuters 
Via Benzinga
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill. 
Via Benzinga
3 High-Yielding Dividend Stocks That Could See Hikes in January
These stocks all pay more than 3% in dividends. 
Via The Motley Fool
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Via Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Gilead will try to win approval for what is now GS-1811, while Jounce develops other immunotherapy drugs. JNCE stock is soaring. 
Via InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major growth stocks and indices. 
Via Benzinga
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
3 Stocks That Could Soar in a Santa Claus Rally
These stocks are primed for a holiday surge. 
Via The Motley Fool
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
The market uptrend is under pressure. 
Via Investor's Business Daily
3 Nasdaq Stocks That Are Up 25% in 3 Months
Should you jump on the bandwagon and buy these surging stocks? 
Via The Motley Fool
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
Via Benzinga
Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot
The twice-yearly option is attractive for patients that don't get adequate treatment from pills alone. 
Via Investor's Business Daily
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Analyzing Gilead Sciences's Short Interest
Gilead Sciences's (NASDAQ:GILD) short percent of float has fallen 15.15% since its last report. The company recently reported that it has 17.56 million shares sold short, which is 1.4% of all regular... 
Via Benzinga
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Why Is Gilead Sciences Stock Sliding Tuesday?
Gilead Sciences Inc (NASDAQ: GILD) shares are trading lower Tuesday after the company reported results from its Phase 2 non-small 
Via Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
Via Benzinga
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tuesday Talk: Where is Santa?
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.